Actively Recruiting
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Led by Tang-Du Hospital · Updated on 2026-04-13
100
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
Sponsors
T
Tang-Du Hospital
Lead Sponsor
Q
Qianxian People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.
CONDITIONS
Official Title
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older and younger than 80 years old
- Confirmed traumatic brain injury
- Admission to hospital within 24 hours after injury
- CT scan showing intracerebral hemorrhage or contusions with or without extracerebral hemorrhage
- Glasgow Coma Scale score of 5 to 12 at enrollment
- Closed head injury
- No infections at admission
- Signed informed consent by patient or legal representative
You will not qualify if you...
- Time of head injury cannot be reliably determined
- Immediate surgery needed due to severe extracranial injury
- Open head injury
- Pregnancy, recent childbirth within 30 days, or active breastfeeding
- Use of Janus kinase inhibitors such as baricitinib, abroctinib, or AG490
- History of dementia or disability before injury
- Severe liver or kidney disease, malignancy with life expectancy under 14 days
- Severe lung infection
- Severe or acute heart failure
- Severe infections within the past 30 days
- History of heart attack
- Known allergy to baricitinib
- Severe low blood cell counts or hemoglobin
- Severe liver or kidney dysfunction
- Currently enrolled in another interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tandu Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China, 710038
Actively Recruiting
Research Team
S
Shunnan Ge, M.D,Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here